Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a ...

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Shares of Biogen Inc. BIIB slipped 1.79% to $124.76 Monday, on what proved to be an all-around positive trading session for ...